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a b s t r a c t 
Complementing whole genome sequencing strategies with high-throughput multiplex RT-qPCR genotyp- 
ing allows for more comprehensive and real-time tracking of SARS-CoV-2 variants of concern. During the 
second and third waves of COVID-19 in Qatar, PCR genotyping, combined with Sanger sequencing of un- 
typeable samples, was employed to describe the epidemiology of the Alpha, Beta and Delta variants. A 
total of 9792 nasopharyngeal PCR-positive samples collected between April-June 2021 were successfully 
genotyped, revealing the importation and transmission dynamics of these three variants in Qatar. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious 
Diseases. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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The emergence of severe acute respiratory syndrome 
oronavirus-2 (SARS-CoV-2) variants of concern (VOC) has 
hreatened the extraordinary public health and vaccination ef- 
orts against coronavirus disease 2019 (COVID-19). These variants, 
hich include Alpha, Beta, Gamma and Delta (Pango lineage B.1.1.7, 
.1.351, P.1 and B.1.617.2, respectively), have now spread to many 
ountries around the world ( WHO, 2021 ). Therefore, in addition to 
he routine surveillance for SARS-CoV-2, it is important to monitor 
he epidemiology of these VOCs to determine the effectiveness of 
accines ( Abu-Raddad et al., 2021a ; Chemaitelly et al., 2021 ) and 
ublic health measures to prevent their spread. ∗ Corresponding author: Mohammad Rubayet Hasan, PhD, D(ABMM), FCCM. Clin- 
cal Molecular Microbiologist, Pathology Sciences, Department of Pathology, Sidra 
edicine, Level 2M, Office H2M-24093, PO BOX 26999, Doha, Qatar. Tel.: + 974 4003 
996; + 974 3003 5501. 
E-mail address: mhasan@sidra.org (M.R. Hasan). 
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201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Soc
icense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) This study employed a previously described multiplex RT-qPCR 
enotyping strategy targeting the 69/70 HV deletion in the spike 
ene and the 3675-3677 SGF deletion in the ORF1a gene to dis- 
inguish the Alpha variant from Beta/Gamma variants ( Vogels et al., 
021 ). The method also included CDC N1 assay to identify ‘other’ 
on-Alpha and non-Beta/Gamma variants for further subtyping. 
ultiplex RT-qPCR was performed, and the results were inter- 
reted with minor modification of the original method. With the 
id of liquid handling robotics, the previously described strategy 
as adapted to scale-up variant screening capacity. To characterize 
he ‘other’ category, sequencing of the N-terminal and receptor- 
inding (RBD) regions of the SARS-CoV-2 surface glycoprotein (S) 
ene was performed (Supplementary data). 
Between 27 March and 19 June 2021, a total of 13,797 ran- 
omly selected SARS-CoV-2-positive NPS specimens were received 
n a weekly basis from the national COVID-19 biorepository at the iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
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Figure 1. Transmission dynamics of SARS-CoV-2 VOCs in Qatar during April-June 2021. A) Number of cases of SARS-CoV-2 VOCs in the overall population by week of swab 
collection; B) Proportion (%) of cases of SARS-CoV-2 VOCs in the overall population by week of swab collection; C) Number of cases of SARS-CoV-2 VOCs in the community 
by week of swab collection; D) Imported cases of SARS-CoV-2 VOCs by week of swab collection. 
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atar Biobank. The number of samples that were received ranged 
rom approximately 10%-47% of the total number of new posi- 
ive cases reported in the country each week ( Figure 1 A) ( https://
ww.data.gov.qa/pages/home/ ). A total of 9792 samples were suc- 
essfully genotyped by the variant PCR, and 4005 samples re- 
ained undetermined because of weak or undetermined RT-qPCR 
t values. Overall, 2970 (30.3%) were B.1.1.7-like, 5500 (56.2%) were 
.1.351/P.1-like, 40 (0.4%) were B.1.375/B.1.258-like and 1282 (13.1%) 
ere ‘other’ variants. Genotyping data were verified by sequenc- 
ng a total of 236 random NPS samples (Supplemental methods). 
CR genotyping results were 88.8%, 99.5% and 100% in agreement 
ith the SARS-CoV-2 lineage assignment by sequencing for B.1.1.7- 
ike, B.1.351/P.1-like and ‘other’ variants, respectively. Additionally, 
 total of 367 random NPS samples from the ‘other’ category were 
equenced (Supplemental methods), of which 354 (96.5%) were 
.1.617.2-like, seven (1.9%) were B.1.617.1-like, three (0.8%) were 
.1-like, one (0.3%) was B.1.617.3-like and one (0.3%) remained un- 
etermined. 
In order to describe the epidemiology of the VOCs, the col- 
ection date, age, sex, nationality, reason for testing, and vacci- 
ation status associated with each sample were extracted from 
 federated, national SARS-CoV-2 database. The second and third 
aves of the COVID-19 pandemic in Qatar were predominantly 
riven by the spread of the B.1.1.7 and B.1.351 variants, respec- 
ively ( Chemaitelly et al., 2021 ). The large third wave, dominated 
y the B.1.351 variant, led to the large contribution of B.1.351/P.1- 
ike cases in the multiplex PCR testing. As the epidemic began to 
ecline in Qatar, large numbers of cases with ‘other’ variants were 
etected ( Figures 1 A and 1 B). The epidemiology of the SARS-CoV- 
 VOCs in the community was similar to the overall epidemiol- 
gy ( Figure 1 C). However, a large number of B.1.1.7-like and ‘other’ 
ariants were detected from the imported cases coincident with 
he outbreaks in India and Nepal ( Figure 1 D) and the importation 
A
53 f the ‘other’ variant significantly declined after targeted travel re- 
trictions were implemented during week 17. 
The ‘other’ variant, which was mostly the ‘Delta’ variant, was 
nitially seen within those of Indian nationality, but it eventually 
pread to other nationalities ( Figure 2 A). Notably, despite the in- 
ux of the Delta variant into the community, it was unable to gen- 
rate a significant outbreak. This is likely due to the high level 
f immunity in the community from the mass vaccination cam- 
aign and previous infection ( Abu-Raddad et al., 2021b ), as well 
s the continuation of various public health measures against the 
pread of SARS-CoV-2. For each variant, most cases during the sec- 
nd and third waves were in individuals aged between 25-44 years 
nd in those who were not fully vaccinated ( Figure 2 B, Supple- 
ental Figure 1). With the decline of the epidemic in Qatar to a 
ow-incidence phase, the resulting distribution of the three dom- 
nant variants (Alpha, Beta, and Delta) suggests a higher effective 
eproduction number or transmissibility of Alpha and Delta vari- 
nts, which makes them more successful versus the Beta variant 
 Campbell et al., 2021 ). 
In conclusion, this study demonstrated that actionable epidemi- 
logical data can be generated by variant PCR so that important 
ublic health decisions can be made in a timely manner. In partic- 
lar, for countries lacking the technical capability and resources for 
arge-scale surveillance based on sequencing, variant PCR may be a 
seful tool in informing national COVID-19 responses and prevent- 
ng the importation of SARS-CoV-2 VOCs and reducing their spread 
n the community. 
uthor contributions 
MRH conceived the idea, co-designed the study, analyzed data 
nd wrote the first draft of the manuscript. MKRK, FM, SS, and 
S performed experiments and analyzed data. PT co-designed the 
M.R. Hasan, M.K.R. Kalikiri, F. Mirza et al. International Journal of Infectious Diseases 112 (2021) 52–54 
Figure 2. Distribution of cases with SARS-CoV-2 VOCs. A) Number of cases of SARS-CoV-2 VOCs by nationality; B) Number of cases of SARS-CoV-2 VOCs by age. 
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